A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. - Wikidata - wikimedia - TriplyDB

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

http://www.wikidata.org/entity/Q36078334

about

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections Systematic review: the efficacy of herbal therapy in inflammatory bowel disease Biological treatment of Crohn's disease.Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.Use of thiopurines in inflammatory bowel disease: Safety issues.Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.Golimumab for the treatment of ulcerative colitis.Clinical markers of Crohn's disease severity and their association with opiate use.Risk of infections associated with biological treatment in inflammatory bowel disease.Inflammatory bowel disease cause-specific mortality: a primer for clinicians Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis.Cancer and immunomodulators in inflammatory bowel diseases.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota Combination therapy for the treatment of Crohn's disease.The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be?Effects of cytomegalovirus infection on the prognosis of inflammatory bowel disease patients.Prevalence and incidence of antimicrobial-resistant organisms among hospitalized inflammatory bowel disease patients.Novel Immunotherapies for Autoimmune Hepatitis.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.Management of the elderly patients with inflammatory bowel disease: practical considerations.Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.Personalizing therapy for inflammatory bowel diseases.Targeting TNF-α for the treatment of inflammatory bowel disease.Medical management of crohn disease.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Positioning therapy for Crohn's disease.An update on medical management on Crohn's disease.Drug Management in the Elderly IBD Patient.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.

P2860

Q26750190-B9259CC1-9DBB-4BFC-9DCF-A2782F5F5379 Q26799615-C7DCFF7D-69D5-4154-B080-4EAF1A876316 Q27004516-021E102E-775F-491B-B5B9-9E1699B8EA2C Q33354991-4898CE27-67A5-412D-9C92-6C73D77AECFE Q33564263-2493CC9D-0493-49EF-AB05-0CC9EE4F5389 Q33621267-C0080D9A-672A-41BA-8546-D3EA7C10DBBF Q33725615-6ABD827C-EE66-4E1F-94A2-7E11F09F3C2B Q33852257-25B3BBFD-ACD1-4087-9C78-70D285EBA407 Q34443893-5B7AA30E-561C-471E-B4CA-2D45ECFD83CD Q34552028-4B20973D-77B3-47BB-B014-EA69465FE61B Q34570452-F05E1B85-F1E9-44D3-9FB7-73CBFD18C445 Q35060557-0FEC3BCA-4194-4D32-935A-24A63308838E Q35534959-0D24CDEC-EF5E-4C60-8A64-4915D453EE73 Q35559305-3BE47F05-BCCD-4CFF-81A1-A9269521FF54 Q35572174-80ECEB7F-AE4C-4548-ADC5-677D9D5E231D Q35686918-15166CEE-0D1B-4CE3-A402-5F857C7E30E6 Q35690314-4C3A5C5B-CEE7-40CB-A637-5B6C407408B6 Q35714202-97CD816D-33F2-4658-B8D2-85835AB356CE Q36026672-185C1A7B-F388-4EBE-8D16-EB38E501CFDD Q36522931-233FFA47-258A-4713-AF04-C696A68613F1 Q37406552-242F6955-815A-4DF0-B0C8-56006FB52AA3 Q37525670-26CEC034-B1D1-4B38-9E45-3CAF68A19F17 Q37607111-6B75CC9A-69E6-49C8-AA6E-989886022096 Q37609746-5A8842EC-6CDA-4BCD-8A8B-EB6F9CF20B07 Q37656048-A483C629-2AB2-41A0-8586-F5B0A6F5CD8C Q37721906-866FD747-614C-40E1-BDA9-A6B1380F24BE Q38086355-8EEED237-E583-441D-BA94-10AAECCAEA3D Q38104612-3D46DF9F-5BD6-4D3C-92B6-0B5F3AD6291F Q38122069-B4EA4848-B097-4D0B-8B11-981238AE0225 Q38122070-696E1E8E-D02E-4E4B-A2CB-34C097296242 Q38132279-6BBCC4C8-6E86-4088-AD18-5D9D27E12AD8 Q38160905-55803A91-DA36-4F43-A740-30A4561E44CE Q38179378-FF2DBAB8-B6F0-45AC-8A6D-C3339C3B58DA Q38197891-5372873C-9F1E-470E-9351-B82C321E86BF Q38200554-92F9779E-C3B8-4877-B8D3-152ED238AC5A Q38270674-833441A7-637B-4349-8510-16128913AEEC Q38330651-86D8E961-DAEF-4227-A076-5F444B75F8B3 Q38364465-5E96703C-38E0-4B1F-A245-AFEE8CC92A94 Q38365848-6AA62DB1-2EF2-47F6-8DD1-190DC5263039 Q38394816-6779297F-E9F5-4BA3-8785-38CCEB722646

P2860

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

http://www.wikidata.org/entity/Q36078334

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

A pooled analysis of infection ...... th inflammatory bowel disease.

@ast

A pooled analysis of infection ...... th inflammatory bowel disease.

@en

type

label

A pooled analysis of infection ...... th inflammatory bowel disease.

@ast

A pooled analysis of infection ...... th inflammatory bowel disease.

@en

prefLabel

A pooled analysis of infection ...... th inflammatory bowel disease.

@ast

A pooled analysis of infection ...... th inflammatory bowel disease.

@en

P1433

Q36078334-5E4A88C8-DC5B-4537-BC9D-51371196C8CC

P1476

Q36078334-9B6D63B1-DB1B-4402-B0B1-F9DB3224F879

P2093

Q36078334-0085F8C2-7F42-467C-BE6F-B6F722EEF15A

Q36078334-0C0A91C6-93D9-481E-818D-D91DCE59BFF4

Q36078334-1DCBEB19-FA4D-47B2-AEBC-1A19FC92A54C

Q36078334-58D793FF-6908-40DB-9FC0-F275ECD272EE

Q36078334-8365B8FF-4071-4A8D-BE97-931B16F326F6

Q36078334-F26DA26D-E8DD-4A6E-8114-4186C2BCC901

Q36078334-FCCD23AB-0170-4C2E-B317-C5342A811947

P2860

Q36078334-0B371F4C-AFD0-450B-8A69-E40E1DF0CD96

Q36078334-0F03C876-C706-40FC-A0E9-76B713CFA48B

Q36078334-2B146152-C8CD-4795-8287-D5E75B9E3786

Q36078334-33BCC76D-F153-47CA-95ED-A755975F3ADF

Q36078334-4495B22C-305A-4F44-AB0B-83681D1CC006

Q36078334-7F3F5C6E-E469-4674-8018-AA408158997C

Q36078334-888ADD34-5E26-4150-8912-FADC286F596E

Q36078334-94B9EEFC-FFB8-462D-A514-034253DBF44B

Q36078334-9E8E2F25-81C9-4C00-9C6B-A4E42E6E8C55

Q36078334-A5AF9497-25D0-43D4-A503-3BBABEE82EBA

P304

Q36078334-666826DC-FE09-4E8D-99FA-87AD7492B177

P31

Q36078334-60782920-0649-4819-8ACE-37AB13F9A934

P356

Q36078334-F2F4EB11-843D-44AB-9D16-7799C68EF47D

P407

Q36078334-C81DF80E-E306-49EA-889C-6793AB633311

P433

Q36078334-F8FD6C1C-13CA-4179-AB40-B0EDC67D65D2

P478

Q36078334-A95C87F5-5BA3-4F21-AC4B-1998A3935763

P50

Q36078334-29198090-834A-4ACD-9646-B55C632891D2

Q36078334-3DCAADE6-D028-44FE-B081-935A3B7DA13E

Q36078334-48EA7F2E-E9BD-4F6C-86DB-934CA6F5C299

P577

Q36078334-E7B5C2C2-FFA1-464A-B1D5-51C1A5B6C362

P5875

Q36078334-FC876892-E613-4EC1-9A38-9C27B57A9591

P698

Q36078334-E88F8F01-81D5-4A11-970C-A28AA8D59D06

P921

Q36078334-8C98439A-381A-4696-BF64-312481A30F6B

P932

Q36078334-D79CE7E5-8919-452F-9996-A5C1D6DE8BB3

P356

P1433

The American Journal of Gastroenterology

P1476

A pooled analysis of infection ...... th inflammatory bowel disease.

@en

P2093

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Freddy Cornillie

http://www.w3.org/2001/XMLSchema#string

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Jennifer Montello

http://www.w3.org/2001/XMLSchema#string

Linda Tang

http://www.w3.org/2001/XMLSchema#string

Marion Blank

http://www.w3.org/2001/XMLSchema#string

Robert H Diamond

http://www.w3.org/2001/XMLSchema#string

P2860

Methotrexate for maintenance of remission in Crohn's disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

How to improve the safety of biologic therapy in Crohn's disease.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Review article: maintenance treatment of Crohn's disease.

Adalimumab safety in global clinical trials of patients with Crohn's disease.

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.

Thiopurine therapy in inflammatory bowel disease.

P304

1051-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2012.89

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

William Jeffery Sandborn

P577

2012-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225053112

http://www.w3.org/2001/XMLSchema#string

P698

22613901

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

3390465

http://www.w3.org/2001/XMLSchema#string